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Abstract The purpose of this study was to determine whether
lysyl oxidase (LOX) is a useful marker of metastasis in gastric
cancer (GC) patients in combination with tumor markers
carcino-embryonic antigen (CEA), carbohydrate antigen 724
(CA724), carbohydrate antigen 19-9 (CA19-9), and carbohy-
drate antigen 125 (CA125). There were 215 GC patients (67
without metastasis, 102 with lymph node metastasis, and 46
with peritoneal metastasis) who presented to the Affiliated
Cancer Hospital of Guangxi Medical University between
May 2009 and November 2012 that were enrolled in this
study. The LOX expression level and the serum concentration
of the four tumor markers were evaluated preoperatively. All
patients underwent computed tomography (CT) and ultraso-
nography (US) before surgery. Statistical analysis, including
receiver operating characteristic (ROC) curve analysis, area
under the curve (AUC) analysis, and logistic regression anal-
ysis, was performed to evaluate the diagnostic value of these
markers in predicting metastasis in GC. For predicting lymph
node metastasis in GC, the sensitivity of LOX, CEA, CA724,
CA199, and CA125 was 44.12, 12.75, 21.57, 23.53, and
15.69 %, respectively, and increased to 79.41 % in combina-
tion. For predicting peritoneal metastasis in GC, the sensitivity
of these markers was 56.52, 23.91, 34.78, 36.96, and 34.78 %,
respectively, and increased to 91.30 % in combination. Com-
bining LOX with CEA, CA724, CA199, and CA125 could
increase the sensitivity of predicting lymph nodes metastasis
and peritoneal metastasis in GC. Surgeons can use these
markers to determine the best treatment options for patients.
Additional large-scale, prospective, multicenter studies are
urgently needed to further confirm the results of this study.
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Introduction
Gastric cancer (GC) is the fourth most common cancer and the
second leading cause of cancer deaths worldwide [1]. Nearly
half of GC cases occur in China, with an overall 5-year
survival rate of approximately 20 % [2]. Most GC cases are
diagnosed in advanced stages [3], and thus the opportunity for
radical surgery is lost. Lack of early detection and limited
treatment options contribute to the poor prognosis in GC [4].
As the prognosis of GC patients is closely related to timely
diagnosis and appropriate treatment, an effective tumor bio-
marker is urgently needed for screening and diagnosis [5].
Advances in basic research and molecular biology mean that it
should now be possible to detect effective tumor biomarkers
to diagnose GC [6], thereby improving treatment options for
patients with advanced GC metastasis.
Lysyl oxidase (LOX) is a copper-dependent amine oxidase
encoded by members of a five-gene family that includes LOX
and four LOX-like proteins (LOXL 1–4) [7]. LOX controls
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both the structure and the tensile strength of the extracellular
matrix and thus preserves tissue integrity [8]. Numerous stud-
ies have highlighted the role of LOX as a marker of tumor
progression and metastasis, such as in bronchogenic carcino-
ma and in breast cancer, colorectal cancer, and ovarian cancer
[9–12]. However, to the best of our knowledge, no studies
have investigated the correlation of LOX expression and it
predicts information for metastasis in GC patients, in condi-
tion of combine LOX with other tumor markers, such as
carcino-embryonic antigen (CEA), carbohydrate antigen 724
(CA724), carbohydrate antigen 19-9 (CA19-9), and carbohy-
drate antigen 125 (CA125).
The present study analyzed the association between LOX
expression and its diagnostic significance for metastasis GC,
in condition of combine LOX with serum tumor markers
CEA, CA724, CA125, and CA199.
Materials and methods
Patients and tissue samples
This study was approved by the Research Ethics Committee
of the Affiliated Cancer Hospital of Guangxi Medical Univer-
sity in China. There were 215 patients with GC who were
diagnosed in the hospital between May 2009 and November
2012 that were enrolled in this study. None of the patients had
received preoperative adjuvant chemotherapy or radiotherapy.
Written informed consent was obtained from all the patients.
Fresh GC specimens were obtained by preoperative gastros-
copy and were fixed in 10 % formalin and embedded in
paraffin, and pathological examination was performed. Fur-
ther postoperative pathological analysis was done for surgery
patients. All the specimens were handled and anonymized
according to ethical and legal standards. All the GC patients
underwent diagnostic imaging with computed tomography
(CT) or ultrasonography (US) prior to the surgery.
According to the pathology report, the GC patients were
divided into the following groups based on their degree of
metastasis: (1, GC patients without metastasis; 2, advanced
GC with lymph node metastasis; and 3, advanced GC with
peritoneal metastasis.
Immunohistochemistry
The expression pattern of LOX in tissue samples was ana-
lyzed with the labeled streptavidin-peroxidase immunohisto-
chemical (IHC) technique. Tissue slides were deparaffinized
in xylene and rehydrated in graded series of ethanol, followed
by heat-induced epitope retrieval in citrate buffer (pH 6.0).
LOX expression was detected using a primary antibody
against LOX (anti-LOX antibody, rabbit polyclonal to LOX,
1/300; Abcam, Cambridge, MA, USA). The degree of
immunostaining was reviewed and scored by two patholo-
gists, taking into account the percentage of positive cells and
the staining intensity, as described by Hu et al. [13]. The
immunostaining was classified into four groups, with the
proportion of cell protein expression categorized as follows
[13]: 0–10 % was recorded as 0, 10–30 % was recorded as 1,
30–50 % was recorded as 2, 50–75 % was recorded as 3, and
>75 % was recorded as 4. Cell protein expression was then
graded according to the sum of the scores: 1, Fig. 1a, negative
expression (−, score of 0–1); 2, Fig. 1b, weak expression (+,
score of 2–3); 3, Fig. 1c, moderated expression (++, score of
4–5); and 4, Fig. 1d, strong expression (+++, score of 6–7).
Blood samples were collected from each patient within 5–7
days before the surgery, and CEA levels were tested with a
fluorescence-enzyme immunoassay. CA724, CA125 (Fujirebio
Diagnostics, PA, USA), and CA19-9 (Immunotech, Marseille,
France) were also measured with an immunoradiometric assay.
The cut-off values for CEA, CA72-4, CA19-9, and CA125,
were defined as 5.0 ng/ml, 5 U/ml, 37 U/ml, and 35 U/ml,
respectively, according to literature reports on a Chinese popu-
lation and the manufacturer’s instructions [14–16].
Statistics
The Chi-square test was used to evaluate the association
between LOX expression and age, gender, tumor location,
differentiation, depth of invasion, metastasis status. The area
under the curve (AUC) of the receiver operating characteristic
(ROC) curve was used to evaluate the predictive value of
LOX, CEA, CA724, CA199, and CA125 for GC with differ-
ent metastasis status. Multivariate logistic regression analysis
was used to establish the diagnostic mathematical model. On
the basis of this model, the prediction value was calculated,
followed by ROC curve analysis. The statistical analysis was
performed with the Statistical Package for the Social Sciences,
version 16.0 (SPSS 16.0), with a P<0.05 considered to be
significant.
Results
The IHC results revealed that 90 of the 215 (41.86 %) GC
patients had different expression levels of LOX. The LOX
expression pattern and clinic pathological factors are listed in
Table 1. The LOX expression pattern was significantly corre-
lated with tumor metastasis status (P<0.05), but it was not
associated with age, gender, tumor location, differentiation,
and depth of invasion (P>0.05). Overall, the sensitivity of
LOX for predicting metastasis in GC (lymph node metastasis
and peritoneal metastasis) was 47.97 %. For predicting lymph
node metastasis in GC, the sensitivity of LOX expression was
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Fig. 1 a Negative expression of
lysyl oxidase (LOX), b weak
expression of LOX, c moderate
expression of LOX, and d strong
expression of LOX
Table 1 Relationship between
LOX expression and clinicopath-













<55 year 109 68 9 17 15 0.21
≥55 year 106 51 12 24 19
Gender
Male 95 49 13 16 17 0.26
Female 120 70 8 25 17
Tumor location
Pylorus 70 37 6 13 14 0.33
Gastric corpus 54 26 8 9 11
Gastric fundus 91 56 7 19 9
Differentiation
Poor 96 58 9 16 13 0.61
Well+intermediate 109 61 12 25 11
Depth of invasion
Mucosa 28 16 5 5 2 0.35
Muscular layer 42 21 6 7 5
Serosa 145 82 10 29 27
Metastasis status
Without metastasis 67 48 8 7 4 0.00
LN metastasis 102 57 9 25 11
Distance metastasis 46 20 4 7 15
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44.12 %, and this increased to 56.52 % for predicting perito-
neal metastasis.
In all the GC patients, preoperative levels of CEA, CA724,
CA19-9, and CA125 were above the cut-off levels (13.49,
21.40, 23.72, and 18.60 %, respectively). The effect estimates
of diagnostic tests of the differentmarkers are shown inTable 2
and Table 3. In predicting lymph node metastasis in GC,
CA199 had the highest sensitivity (23.53 %), specificity
(85.07 %), and accuracy (47.93 %) among the four serum
tumor markers, and CEA had the worst sensitivity (12.75 %),
specificity (92.54 %), and accuracy (44.38 %). In GC patients
with peritoneal metastasis, CA199 had the highest sensitivity
(36.96 %), and CEA had the lowest sensitivity (23.91 %). As
the degree of metastasis increased, the positive rate of serum
CEA, CA724, CA199, and CA125 increased. The sensitivity
of the diagnostic imaging (CT or US) in lymph node metasta-
sis patients and peritoneal metastasis patients was low, (7.84
and 15.22 %, respectively). The positive likelihood ratio and
negative likelihood ratio of these markers in detecting differ-
ent metastasis in GC are also presented in Table 2 and Table 3.
As the sensitivity of a single serum tumor marker in
predicting metastasis in GC was low, its potential in clinical
application would be limited. Therefore, we analyzed the sen-
sitivity when these markers were combined and obtained the
AUC of ROC curve. We then calculated their diagnostic values
in GC with different metastasis status. The combined markers
yielded an ROC value of 0.682, which was significantly higher
than that of the single marker (P<0.05) and better able to
distinguish lymph node metastasis in GC (Table 2 and
Fig. 2). In peritoneal metastasis patients, the ROC value of
the five markers combined was 0.787, higher than each single
marker (Table 3 and Fig. 3).
Discussion
Metastasis is one of the main causes of death in patients with
GC tumors [17]. Early detection of metastasis and appropriate
treatment are of critical importance for patient outcomes. For
example, surgical resection with extensive lymphadenectomy
was shown to result in better outcomes in GC involving the
lymph nodes [18], and the positive effect of neoadjuvant
intraperitoneal and systemic chemotherapy on patients with
advanced GC and peritoneal dissemination has been demon-
strated [19, 20].
CT and US can help to predict metastasis GC, but
many studies have shown that these are not reliable
indicators of metastasis [21, 22]. Our data showed that
the sensitivity of these diagnostic imaging modalities in
lymph node metastasis patients and peritoneal metastasis
patients was only 7.84 and 15.22 %, respectively. The
predictive value of PET/CT was high in local lymph
node metastasis and distant metastasis in GC patients
[23]. However, it is costly, and most patients are unable
to afford the procedure. Laparoscopic exploration is less
invasive than open surgery for diagnosing malignant
abdominal disease [24]. However, it is also costly and
time-consuming, and surgeons are reluctant to undertake
it. Several of the most frequently used tumor markers,
such as CEA, CA724, CA199, and CA125, provide
additional diagnostic information in gastrointestinal ma-
lignancies [25, 26], but the sensitivity of any one mark-
er alone is not sufficient [27]. In our group, the sensi-
tivity of CEA, CA724, CA199, and CA125 in the GC
patients with lymph node metastasis was only 12.75,
21.57, 23.53, and 15.69 %, respectively. In the perito-
neal metastasis patients, the sensitivity of these four
markers was 23.91, 34.78, 36.96, and 34.78 %, respec-
tively. As the diagnosis of GC is most often performed
when the tumor is at an advanced stage [28], there is an
urgent need to identify new markers (diagnostic
methods) to provide appropriate treatment and improve
prognoses.
LOX was initially reported as a copper-dependent
amine oxidase responsible for the catalysis of collagen
and elastin cross-linking within the extracellular matrix
[29]. A recent study highlighted the role of LOX family
oxidases in promoting cancer metastasis [30]. LOX is
Table 2 Predictive ability of different markers for lymph node metastasis gastric cancer
Tumor marker AUC (95 % CI) Sensitive Specificity Accuracy PLR NLR
LOX 0.599a (0.514–0.685) 44.12 % 71.64 % 55.03 % 1 0.84
CEA 0.562a (0.475–0.649) 12.75 % 92.54 % 44.38 % 0.81 0.92
CA724 0.569a (0.483–0.655) 21.57 % 88.06 % 47.92 % 0.92 0.90
CA199 0.663a (0.578–0.748) 23.53 % 85.07 % 47.93 % 0.89 0.91
CA125 0.574a (0.486–0.661) 15.69 % 88.06 % 44.38 % 0.67 0.97
Combination 0.682 (0.602–0.763) 79.41 % 31.34 % 76.33 % 2.79 0.55
AUC area under the curve, CI confidence interval, PLR positive likelihood ratio, NLR negative likelihood ratio
aP<0.05 compared with combination of all markers
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highly expressed in invasive tumors, such as uveal
melanoma, colorectal cancer, and gastric cancer, and it
is closely associated with metastasis and poor patient
outcomes [12, 29, 31]. Our study demonstrates that
increased expression of LOX is correlated with an ad-
vanced stage of GC and that it may contribute to tumor
development. This finding is consistent with that of
Zhang et al. [29]. In lymph node metastasis and perito-
neal metastasis in GC, the rate of LOX overexpression
was 44.12 and 56.52 %, respectively, in the current
study. Therefore, LOX is a correlative biomarker of
metastasis in GC.
However, based our results, the sensitivity and accuracy of
LOX alone are limited (around 50 % and no more than 61 %,
respectively). Therefore, the use of LOX alone does not meet
the requirements of clinical practice. Several studies found
that a combination of different tumor marker may improve
diagnostic accuracy in gastrointestinal tract malignancies
compared with single biomarkers alone. For example, Emoto
et al. [32] showed that the combined use of CEA, CA199,
CA725, and CA125 may improve the sensitivity of these
biomarkers in detecting peritoneal metastasis in GC. Chen
et al. [33] revealed that combining CA724 with CEA and
CA199 considerably improves the sensitivity of these bio-
markers in detecting GC, without impairing specificity. The
choice of serum tumor markers to be combined with LOX
requires further investigation to determine how to improve the
sensitivity of these biomarkers in the detection of metastasis in
GC.
We carefully selected other serum tumor markers
correlated with tumor invasion and combined these with
LOX to improve the sensitivity of these in detecting
metastasis in GC. Several studies revealed that CA724
and CA199 are correlated with invasive GC, lymph
Table 3 Predictive ability of different marker for peritoneal metastasis gastric cancer
Tumor marker AUC (95 % CI) Sensitive Specificity Accuracy PLR NLR
LOX 0.639a (0.542–0.736) 56.52 % 62.13 % 60.93 % 0.41 0.19
CEA 0.741a (0.667–0.815) 23.91 % 89.35 % 75.35 % 0.62 0.23
CA724 0.689a (0.607–0.772) 34.78 % 82.25 % 72.09 % 0.53 0.22
CA199 0.690a (0.605–0.775) 36.96 % 79.88 % 70.70 % 0.50 0.21
CA125 0.754a (0.671–0.836) 34.78 % 85.80 % 74.88 % 0.67 0.21
Combination 0.787 (0.717–0.858) 91.30 % 20.59 % 29.30 % 0.52 0.14
AUC area under the curve, CI confidence interval, PLR positive likelihood ratio, NLR negative likelihood ratio
aP<0.05 compared with combination of all markers
Fig. 2 Receiver operating
characteristic (ROC) curve of
single and combined markers in
predicting lymph node metastasis
in gastric cancer (GC)
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node involvement, and tumor stage [34–40] and that
combined use of CEA with CA724 and CA199 consid-
erably improves the positive rate, without impairing the
specificity [41]. However, our results showed that the
preoperative positivity of CEA, CA724, CA19-9, and
CA125 was extremely low, making it a poor biomarker
of lymph node metastasis and peritoneal metastasis in
GC. When we combined all the markers, their sensitiv-
ity in detecting lymph node metastasis in GC was
79.41 %. The sensitivity for GC with peritoneal metas-
tasis was 91.30 %, which was higher than when a
single marker was used (Table 2 and Table 3). The
ROC curve analysis also revealed that the combination
of all markers yielded a value of 0.682 for GC with
lymph node metastasis and 0.787 for GC with peritone-
al metastasis. These values were significantly higher
than the sensitivity with one marker (P<0.05, Table 2
and Table 3).
Interestingly, our study showed that in the GC patients with
lymph node metastasis, CA125 was positive in only 15.69 %
of cases, but it was positive in 34.78 % of GC cases with
peritoneal metastasis. This finding is consistent with that
reported in a study by Emoto et al. [32], who found that
CA125 was correlated with the degree of peritoneal dissemi-
nation in GC and that it was highly sensitive in predicting
peritoneal metastasis.
We did not evaluate other tumor markers, such as
carbohydrate antigen 50, alpha fetal protein (AFP), and
carbohydrate antigen 242, because these markers are not
commonly measured in GC patients, and very few stud-
ies have shown any association between these markers
and lymph node or peritoneal metastasis in GC. For
example, most AFP-positive GC was correlated with
liver metastasis [33].
In summary, we found that LOX is a correlative tumor
biomarker for GC with lymph node metastasis and peritoneal
metastasis in a Chinese population. The combined use of LOX
with other markers (LOX+CEA+CA724+CA199+CA125)
could improve their sensitivity in predicting metastasis in GC.
Our study has several limitations. First, this is a retrospec-
tive analysis with a relatively small sample from a single
institute. A large, prospective, multicenter study is needed to
demonstrate the predictive value of LOX in GC metastasis in
combination with other tumor markers. Second, we could not
accurately distinguish the metastasis N stage and the perito-
neal dimensional status (P0, P1, P2, and P3) because LOX
expression was evaluated by qualitative detection, not by
quantitative determination, and our sample size was not large.
Third, uncontrolled or unmeasured confounding factors, such
as selection bias in GC patients and potential laboratory errors
in evaluating LOX expression, may have produced bias.
Conclusions
The combined use of LOX with CEA, CA724, CA199, and
CA125 could increase the sensitivity of predicting lymph
nodes metastasis and peritoneal metastasis in GC. Surgeons
can use these markers to determine the best treatment options
for patients. Additional large-scale, prospective, multicenter
studies are urgently needed to further confirm the results of
this study.
Fig. 3 Receiver operating
characteristic (ROC) curve of
single and combined markers in
predicting peritoneal metastasis in
gastric cancer (GC)
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